Table 3 Patients with CA125 response or stabilization
Pt. | Age | Prior chemo regimens | Response latest treatment | Interval since latest treatment | CA125 at study entry (U/mL) | CA125 baseline for response (U/mL) | CA125 nadir (U/mL) | CA125 response (duration) | CT scan response | On study |
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Â | (study day) | (study day) | Â | Â | Â |
Confirmed | ||||||||||
202 | 76 | 4 | PD | 28 wks | 507 | 507 | 379 | Stable 23 wks | Target lesions stable at 24Â weeks but new non-measurable lymphadenopathy | 23 wks |
(d1) | (d91) | |||||||||
208 | 58 | 1 | PR | 56 wks | 4939 | 4939 | 2326 | Minor 10 wks | Non-measurable disease only (ascites). New pleural effusion at 28Â weeks | 34 wks |
(d1) | (d161) | Stable 32 wks | ||||||||
219 | 48 | 1 | CR | 54 wks | 214 | 408 | 189 | Major 10 wks | No abnormality on baseline or follow up scans | 68 wks |
(d55) | (d163) | Stable 57 wks | ||||||||
228 | 62 | 3 plus immuno-therapy | PD | 16 wks | 1455 | 2215 | 98 | Major 71 wks | 32% increase in measurable disease at 12Â weeks, reduced to 24% at 28Â weeks and 21% at 42Â weeks | 80 wks |
(d33) | (d161) | |||||||||
Unconfirmed | ||||||||||
220 | 54 | 3 | PR | 20 wks | 593 | 2442 | 1387 | Minor 7 wks | At 14Â weeks target lesions stable but new ascites | 21 wks |
| Â | Â | Â | Â | Â | Â | (d55) | (d90) | Stable 11 wks | Â | Â |